The global nanomedicine market was estimated at USD 178.29 billion in 2022 and it is expected to surpass around USD 541.99 billion by 2032, poised to grow at a CAGR of 11.76% from 2023 to 2032.
Key Pointers
Report Scope of the Nanomedicine Market
| Report Coverage | Details |
| Market Size in 2022 | USD 178.29 billion |
| Revenue Forecast by 2032 | USD 541.99 billion |
| Growth rate from 2023 to 2032 | CAGR of 11.76% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Covered | Abbott Laboratories; Combi Matrix Corporation; Celgene Corporation; Nano spectra Biosciences, Inc.;General Electric; Johnson & Johnson Services; Inc.; Mallinckrodt Pharmaceuticals;Merck & Co., Inc.;Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Arrowhead Pharmaceuticals, Inc. |
Development and commercialization of the techniques that holds potential to significantly improve the administration of drugs and disease management is expected to drive the adoption of nanomedicines in this market. Furthermore, growing adoption of nanotechnology-based drug delivery methods coupled with inefficiency of conventional therapeutics in disease treatment has driven the nanomedicine market growth.
According to the reports, COVID-19 has a positive effect on the market for nanomedicine. This resulted from an increase in the need for nanomedicines used for the treatment of medical conditions that resemble cancer. Additionally, applications of nanomedicine opened up new possibilities for the introduction of innovative solutions designed for the prevention, detection, and treatment of viral diseases such as the COVID-19 virus thereby boosting the nanomedicine industry growth.
Furthermore, the active participation of well-established pharmaceutical companies in the development of novel Nano science-based therapeutics is anticipated to influence the growth of this market. Moreover, advancements in nanotechnology and its expanding applications in preventive interventions, early disease diagnosis, prevention of chronic as well as acute disorders, and prophylaxis of acute as well as chronic disorders are the factors expected to spur the nanomedicine industry growth.
Manufacturers are benefiting from significant growth prospects in the global market as a result of the growing demand for nanomedicines. The field of nanomedicine is growing in the healthcare sector and is being more widely used in medical and healthcare settings. Furthermore, it is projected that the active involvement of prominent pharmaceutical companies in the production of cutting-edge nanoscience-based medicines will have an impact on the development of this industry.
Government organizations are likely to increase their R&D funding, opening up attractive opportunities for the nanomedicine market expansion. Governmental funding aids in accelerating massive capital-intensive projects. For instance, the National Science Foundation stated in August 2020 that it will invest a total of $84 million during five years in re-establishing the National Nanotechnology Coordinated Infrastructure in order to advance Nano scale engineering, science, and technology.
Moreover, The Canadian Institutes of Health Research (CIHR) and the Canadian Space Agency (CSA) are funded by the Canadian government for research in the field of nanomedicine and regenerative medicine. Therefore, it will drive the nanomedicine market growth in the coming years.
Regional Insights
North America dominated the regional market with a share of 47.58% in 2021. During the course of the forecast period, the region is expected to retain its leadership. This expansion can be ascribed to the existence of expanding alliances between businesses working in this area and nanomedicine start-up companies. Furthermore, the region's significant participation in the industrial sector is due to the support from governmental bodies combined with increased R&D expenditures.
The expansion of the market is driven by an increase in research funding and a rise in demand for life-threatening illness prophylaxis in the United States. The nation also boasts a sizable number of manufacturing firms with active strategic ventures in nanomedicine.
Nanomedicine Market Segmentations:
By Application
By Indication
By Molecule Type
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Application Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Nanomedicine Market
5.1. COVID-19 Landscape: Nanomedicine Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Nanomedicine Market, By Application
8.1. Nanomedicine Market, by Application, 2023-2032
8.1.1 Therapeutics
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Active Implants
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. In-vitro Diagnostics
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Drug Delivery
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. In-vivo Imaging
8.1.5.1. Market Revenue and Forecast (2020-2032)
8.1.6. Implants
8.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Nanomedicine Market, By Indication
9.1. Nanomedicine Market, by Indication, 2023-2032
9.1.1. Clinical Oncology
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Infectious diseases
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Clinical Cardiology
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Orthopedics
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Nanomedicine Market, By Molecule Type
10.1. Nanomedicine Market, by Molecule Type, 2023-2032
10.1.1. Nanoparticles
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Nano Shells
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Nano Tubes
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Nano Devices
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Nanomedicine Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Application (2020-2032)
11.1.2. Market Revenue and Forecast, by Indication (2020-2032)
11.1.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Application (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Application (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Application (2020-2032)
11.2.2. Market Revenue and Forecast, by Indication (2020-2032)
11.2.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Application (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Application (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Application (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Indication (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Application (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Indication (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Application (2020-2032)
11.3.2. Market Revenue and Forecast, by Indication (2020-2032)
11.3.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Application (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Application (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Application (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Indication (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Application (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Indication (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Application (2020-2032)
11.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.4.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Application (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Application (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Application (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Indication (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Application (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Indication (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Application (2020-2032)
11.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.5.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Application (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Application (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
Chapter 12. Company Profiles
12.1. Abbott Laboratories
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Combi Matrix Corporation
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Celgene Corporation
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Nano spectra Biosciences, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. General Electric
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Johnson & Johnson Services, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Mallinckrodt Pharmaceuticals
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Merck & Co., Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Pfizer, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Teva Pharmaceutical Industries Ltd.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers